The Pharmacy and Poisons Board (PPB) has ordered all pharmaceutical outlets, healthcare facilities, and healthcare professionals, immediately cease the distribution and sale of three batches of Paracetamol 1000mg/100ml Injection.
According to the board, the batches identified in the Kenyan market have exhibited a colour change.
The Board has also ordered the cessation of the issuance or use of the outlined product batches and instructed that they be returned to the nearest healthcare facility or respective suppliers.
“In execution of the foregoing mandate, the Board draws public attention to the detection of substandard batches of Paracetamol 1000mg/100ml Injection identified in the Kenyan market, which have exhibited a color change,” read the statement in part.
“In view of the above, the Board advises all pharmaceutical outlets, healthcare facilities, healthcare professionals, and members of the public to immediately cease further distribution, sale, issuing, or use of the outlined product batch and return the same to their nearest healthcare facility or respective suppliers.”
PPB Orders Immediate Halt on Distribution and Sale of Paracetamol Injection
The flagged batches include:
1. Lumidol Injection: Batch Numbers CM4594007, CM4594008, and CM4594009, Manufactured by KamlaAmrut Pharmaceutical LLP, India.
2. Blink Injection: Batch Numbers CS4594005 and CS4594004 Manufactured by KamlaAmrut Pharmaceutical LLP, India.
3. Paragen injection: Batch Number K4290027, Manufactured by KamlaAmrut Pharmaceutical LLP, India.
Also Read: Study Reveals How Children in Nairobi Estates Are Exposed to Poisonous Gas
Poisons Board Recalls S-Prazo and Augmentin
At the same time, the PPB has alerted the public to a product mix-up involving S-Prazo (Esomeprazole 40mg), Batch No. SPZ404. A strip of Levofloxacin 500mg tablets was found in a pack of Esomeprazole capsules.
The Board has directed all pharmaceutical outlets, healthcare facilities, professionals, and members of the public to immediately stop distributing, selling, issuing, or using the affected batch and to return it to the nearest healthcare facility or supplier.
Additionally, the Pharmacy and Poisons Board has warned the public about falsified Augmentin 1g (Batch SGS2) and Augmentin 625mg (Batch numbers 8X3K and EU7C) found in the Kenyan market.
“In view of the above, the Board advises all pharmaceutical outlets, healthcare facilities, healthcare professionals, and members of the public to immediately further distribution, sale, issuing, or use of the outlined product batch and return the same to their nearest healthcare facility or respective suppliers,” PPB said.
Also Read: Govt Orders Quarantine of Popular Cancer Drug
The Board encouraged the public to report any suspected cases of sub-standard medicines or adverse drug reactions to the nearest healthcare facility or the Pharmacy and Poisons Board through its official channels.
The Pharmacy and Poisons Board is the National Regulatory Authority under the Ministry of Health, established under the Pharmacy and Poisons Act Cap 244, Laws of Kenya (hereinafter “the Act”) mandated to protect and promote the health of the public by regulating the profession of pharmacy and ensuring access to quality, safe and efficacious health products and technologies.
Follow our WhatsApp Channel and X Account for real-time news updates